CoChat

Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer

Wetherill, Yelena B., Hess-Wilson, Janet K., Comstock, Clay E.S., Shah, Supriya A., Buncher, C. Ralph, Sallans, Larry, Limbach, Patrick A., Schwemberger, Sandy, Babcock, George F., Knudsen, Karen E. · 2006 · Molecular Cancer Therapeutics
Cited by 78

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Prostatic adenocarcinomas depend on androgen for growth and survival. First line treatment of disseminated disease exploits this dependence by specifically targeting androgen receptor function. Clinical evidence has shown that androgen receptor is reactivated in recurrent tumors despite the continuance of androgen deprivation therapy. Several factors have been shown to restore androgen receptor activity under these conditions, including somatic mutation of the androgen receptor ligand-binding domain. We have shown previously that select tumor-derived mutants of the androgen receptor are receptive to activation by bisphenol A (BPA), an endocrine-disrupting compound that is leached from polycarbonate plastics and epoxy resins into the human food supply. Moreover, we have shown that BPA can promote cell cycle progression in cultured prostate cancer cells under conditions of androgen deprivation. Here, we challenged the effect of BPA on the therapeutic response in a xenograft model system of prostate cancer containing the endogenous BPA-responsive AR-T877A mutant protein. We show that after androgen deprivation, BPA enhanced both cellular proliferation rates and tumor growth. These effects were mediated, at least in part, through androgen receptor activity, as prostate-specific antigen levels rose with accelerated kinetics in BPA-exposed animals. Thus, at levels relevant to human exposure, BPA can modulate tumor cell growth and advance biochemical recurrence in tumors expressing the AR-T877A mutation. [Mol Cancer Ther 2006;5(12):3181–90]

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-06-0272

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 78

Metadata

Authors
Wetherill, Y. B., Hess-Wilson, J. K., Comstock, C. E. S., Shah, S. A., Buncher, C. R., Sallans, L., Limbach, P. A., Schwemberger, S., Babcock, G. F., & Knudsen, K. E.
Venue
Molecular Cancer Therapeutics
Published
2006-12-01
Volume
5
Issue
12
Pages
3181-3190
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2130070231
Cited by
78
References
6
FWCI
3.49
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer. https://app.cochat.ai/papers/10.1158/1535-7163.mct-06-0272
The paper
Wetherill, Y. B., Hess-Wilson, J. K., Comstock, C. E. S., Shah, S. A., Buncher, C. R., Sallans, L., Limbach, P. A., Schwemberger, S., Babcock, G. F., & Knudsen, K. E. (2006). Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-06-0272

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.